Allosteric inhibitors targeting the autoinhibited conformation of Akt have been shown to be highly specific64 with anti-tumor activity in patient-derived xenograft models of pancreatic, colon, and endometrial cancer65,66 and tumor regression and Akt signaling blockade in advanced solid tumors67. This evidence concerns the gene AKT1 and neoplasm.